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Abstract
EpCAM (epithelial cell adhesionmolecule) was discovered four decades ago as a tumor antigen on colorectal carcinomas. Owing
to its frequent and high expression on carcinomas and their metastases, EpCAM serves as a prognostic marker, a therapeutic
target, and an anchor molecule on circulating and disseminated tumor cells (CTCs/DTCs), which are considered the major source
for metastatic cancer cells. Today, EpCAM is reckoned as a multi-functional transmembrane protein involved in the regulation of
cell adhesion, proliferation, migration, stemness, and epithelial-to-mesenchymal transition (EMT) of carcinoma cells. To fulfill
these functions, EpCAM is instrumental in intra- and intercellular signaling as a full-length molecule and following regulated
intramembrane proteolysis, generating functionally active extra- and intracellular fragments. Intact EpCAM and its proteolytic
fragments interact with claudins, CD44, E-cadherin, epidermal growth factor receptor (EGFR), and intracellular signaling
components of the WNT and Ras/Raf pathways, respectively. This plethora of functions contributes to shaping intratumor
heterogeneity and partial EMT, which are major determinants of the clinical outcome of carcinoma patients. EpCAM represents
a marker for the epithelial status of primary and systemic tumor cells and emerges as a measure for the metastatic capacity of
CTCs. Consequentially, EpCAM has reclaimed potential as a prognostic marker and target on primary and systemic tumor cells.
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1 Introduction
The epithelial cell adhesion molecule (EpCAM) has first been
described in 1979 as a humoral antigen expressed on colon
carcinoma cells [1]. Here, we have summarized the impressive
progress in the biology of EpCAM in the past four decades.
Expression patterns, regulation, and the multiple functions of
EpCAM in normal epithelia, in carcinoma, and in pluripotent
stem cells are reviewed. Furthermore, the clinical implications
and applications related to EpCAM are discussed. Lastly, the
most recently discovered involvement of EpCAM in the reg-
ulation of epithelial-to-mesenchymal transition, which is of
paramount importance during metastases formation and ther-
apy resistance, is delineated.
1.1 Initial description
EpCAM was first described in 1979 as a humoral antigen
recognized by monoclonal antibody 1083-17-1A (Co17-1A
or mAb 17-1A) following inoculation of human colorectal
cancer cells in mice [1]. Today, PubMed-listed publications
on “EpCAM” exceed 8000 entries. Publications have steadily
increased (Fig. 1) reflecting an enhanced interest in EpCAM
along with broadening functional roles.
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1.2 EpCAM cDNA cloning and protein structure
The coding sequence of human EpCAM was deciphered in
1989 and predicted a single transmembrane protein of 314
amino acids (aa) with a 265-aa extracellular domain, a 23-aa
hydrophobic transmembrane domain, and a hydrophilic 26-aa
intracellular domain [2]. In 2014, the crystal structure of the
extracellular domain of EpCAMwas resolved and was shown
to represent heart-shaped homodimers [3].
1.3 Cell adhesion
The first function as a homophilic cell adhesion molecule and
a role in the integrity of epithelium was proposed in conjunc-
tion with the name EpCAM by Litvinov et al. [4]. They re-
ported that ectopic expression of EpCAM in murine fibro-
blasts and mouse mammary carcinoma cells induced cluster-
ing and segregation of cells and reduced invasive growth.
Later on, inhibitory activity towards cadherin-mediated adhe-
sion in epithelial cells was reported [5].
1.4 Proliferation and differentiation
First evidence for a correlation of EpCAM in proliferation and
differentiation surfaced in 1994 [6] and 1996 [7] in
keratinocytes, transformed epithelial cells, and carcinoma cell
lines. In 2004, a role for EpCAM in the regulation of prolif-
eration, migration, and invasion was shown [8, 9]. A role of
EpCAM in differentiation was reported in pluripotent embry-
onic stem cells (ESCs), progenitor cells, and carcinoma stem
cells [10].
1.5 Clinical significance in cancer
Frequent and high-level expression of EpCAM on various
carcinomas (98 out of 131 tested) [11, 12] and metastases
[13, 14], and a correlation with clinical outcome qualified it
as prognostic marker and therapeutic target [15]. EpCAM-
specific antibody Panorex® (edrecolomab; 17-1A) first
attained market approval for treating colorectal carcinomas
in 1995 [16]. Furthermore, EpCAM served to enrich, identify,
and characterize metastatic cells that have disseminated from
primary tumor into blood and bone marrow of advanced car-
cinoma patients [17, 18]. Despite existing challenges,
EpCAM remains the surface antigen of choice in clinical use
to isolate circulating tumor cells (CTCs) with prognostic value
and metastatic potential [15, 19–21].
1.6 EpCAM in non-malignant diseases
A major breakthrough in understanding congenital tufting en-
teropathy (CTE), a severe form of early-onset autosomal re-
cessive diarrhea, was achieved when Mamata Sivagnanam
and colleagues reported on the linkage of CTE with mutations
in the EPCAM gene that precluded its correct expression at the
plasma membrane [22]. Lack of EpCAM expression results in
villus atrophy and in the formation of intestinal tufts, which
eventually induces a dysfunctional intestinal barrier and un-
balanced ion transport [23, 24].
Furthermore, mutations in the 3′-end of the EPCAM gene
induce epigenetic silencing of genes downstream of EPCAM
that are involved in mismatch repair, including the MutL ho-
molog 1 (MLH1) andMutS protein homolog 2 (MSH2) genes.
EPCAM 3′-mutations and subsequent deregulation of MLH1
and MSH2 protein expression are the cause of Lynch syn-
drome (hereditary non-polyposis colorectal cancer
(HNPCC)) [25, 26].
A chronic of major advances on EpCAM in basic research
and clinical application is summarized in Fig. 2.
2 EpCAM gene and protein structure
The human EPCAM gene is encoded on the plus strand of
chromosome 2p21 and consists of 9 exons covering 41.88
kilobases (kb). Exon 1 encodes the 5′-untranslated region
and the signal peptide, exon 2 the EGF-like motif, exon 3
the thyroglobulin domain, exons 4–6 the cysteine-poor part
of the domain, exon 7 the transmembrane domain, exon 8
parts of the intracellular domain, and exon 9 the remaining
intracellular domain and the 3′-untranslated region [27]. A
1.1-kb fragment of the EPCAM promoter sufficient to drive
gene expression and confers epithelial specificity was cloned
[28, 29]. The promoter can be further subdivided in a gene
proximal part composed of 570 base pairs (bp) and a distal
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Fig. 1 Publication numbers retrieved from PubMed using “EpCAM” as a
search term. Two time points of increase in publication numbers are
marked by dashed lines. The first wave of increased publications maps
to the cloning of the EpCAM cDNA in 1989. The second wave coincides
with the description of EpCAM function in proliferation and migration in
2004
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part of 550 bp that act synergistically in EPCAM expression
and are negatively regulated by nuclear factor kappa B
(NF-κB) [29]. Sankpal et al. further described the usage of
an extracellular-regulated kinase 2 (ERK2) binding site within
the EPCAM promoter [30], while Yamashita et al. reported on
the regulation of the EPCAM promoter by a Wnt-β-catenin-
Tcf4 complex in hepatocellular carcinoma cells [31].
Furthermore, the EMT-inducing transcription factor Zeb1 re-
presses EPCAM expression in zebrafish [32].
EpCAM is a transmembrane protein with a single
membrane-spanning domain (23-aa) that connects the larger
extracellular domain (265-aa) to a short intracellular domain
(26-aa) (Fig. 3). The extracellular domain contains a signal
peptide, an EGF-like, cysteine-rich domain, and a
thyroglobulin-like domain, which was initially referred to as
a second EGF-like repeat [36], followed by a cysteine-poor
region [37]. Mass spectrometry and Edman sequencing of the
extracellular domain of EpCAMdemonstrated the cleavage of
the signal peptide after aa 23, resulting in an N-terminus
starting with a modified pyroglutamate [38]. Disulfide bonds
were mapped to Cys27–Cys46, Cys29–Cys59, Cys38–Cys48,
Cys110–Cys116, and Cys118–Cys135 (Fig. 3) [38].
N-Glycosylation of EpCAM has been reported with
no evidence of O-glycosylation [2]. N-Glycosylation
sites have been mapped to Asn74, Asn111, and Asn198
of EpCAM [38]. Initially complete glycosylation of
Asn111, partial glycosylation of Asn74, and no glycosyl-
ation at Asn198 were reported [38]. However, single and
dual mutations of Asn74 and Asn111 revealed that muta-
tions retained a certain degree of glycosylation, which
was lost when all positions including Asn198 were mu-
tated [39]. Loss of glycosylation at this site resulted in
severe reduction of protein stability and half-life at the
membrane from 21 to 7 h [39]. Glycosylation of
EpCAM may impact on EpCAM stability and expres-
sion in tumor cells, as it was found increased in can-
cerous versus healthy tissue [40].
Crystal structure analysis of the extracellular domain of
EpCAM, termed EpEX, at 1.86 Å resolution revealed a
three-partite fold in amino-terminal (puroGlu24–Leu62),
thyroglobulin-like (Ala63–Arg138), and carboxy-terminal
(Val139–Lys265) domains (Fig. 3). The respective ND,
TY, and CD domains are each in contact with the other
two domains, forming a triangle [3]. EpEX molecules
form cis-dimers with strongest interactions between the
TY loop of one EpEX molecule with the βC sheet of a
second molecule [3]. Coarse grain modelling of the
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Fig. 2 Milestones of EpCAM discoveries in basic research (in blue) and in clinical application (in green). ESC: embryonic stem cells, CTE: congenic
tufting enteropathy, iPS: induced pluripotent stem cells, MBC: metastatic breast cancer, CTCs: circulating tumor cells
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in which two helices of the membrane-spanning parts are
symmetrically arranged and cross each other between
Val276 and Val280 [3]. There is so far no structural infor-
mation of the intracellular domain of EpCAM termed
EpICD.
3 EpCAM and cell adhesion
Initial characterization of EpCAM functions was conducted in
murine fibroblasts and L153S mammary carcinoma cells,






















































































Fig. 3 Schematic representation
of the EpCAM protein. EpCAM
is composed of a signal peptide
(SP) that is removed from the
mature protein. Mature EpCAM
comprises an extracellular do-
main (EpEX), a single transmem-
brane domain (TMD), and a short
intracellular domain (EpICD). N-
Terminal (N-domain), thyroglob-
ulin (TY-domain), and C-terminal
domains (C-domain) within
EpEX, as defined by Pavsic et al.
[3], are marked. N- and TY-
domains are cysteine-rich protein
stretches that have initially been
defined as EGF-like domains.
Disulfide bonds involving cyste-
ines, N-glycosylation at aspara-
gines, ubiquitylation at lysines,
and cleavage sites related to reg-
ulated intramembrane proteolysis
of EpCAM (α-, β-, γ-, and ε-
sites) [33, 34] are annotated. The
approximated additional cleavage
site reported by Schnell et al. [35]
is indicated. Sizes are not at scale
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adoption of a spindle-shaped morphology. Ectopic expression
resulted in increased intercellular adhesion and cell aggrega-
tion in suspension, along with the segregation of EpCAM-
positive and EpCAM-negative cells, and a reduced capacity
of fibroblast to grow invasively [4, 41]. Membrane-proximal
thyroglobulin-like domains, initially referred to as a second
EGF-like domain, mediate lateral interactions of EpCAM in
cis on one cell. Membrane-distal EGF-like repeats are re-
quired for interactions of EpCAM in trans on adjacent cells
[42]. Taken together, formation of functional EpCAM tetra-
mers as the initiating event in the formation of cell adhesion
complexes was proposed [42].
Surprisingly, overexpression of EpCAM in epithelial cell
lines that depend on cadherin-mediated cell-cell connections
decreased adhesion by impairing functional adherens junc-
tions through disruption of E-cadherin, α-catenin, and F-
actin interactions [43, 44]. EpCAM’s capacity to inhibit
cadherin-mediated adhesion in breast epithelial cells
depended on phosphoinositide 3-kinase (PI3K) and its shifted
interaction with N-cadherin to EpCAM [45].
Knockout of EpCAM in mice supported its role in orches-
trating the structure and functionality of epithelium in the in-
testinal tract [46–48]. EpCAM knockout induced an abnormal
placental development associated with death in utero at ges-
tation day E12.5 [46]. Subsequent knockouts did not repro-
duce an embryonic lethality; however, mice died of severe
intestinal erosion and hemorrhagic diarrhea shortly after birth
[44, 45]. Intestinal defects were reminiscent of human CTE
where mutations cause a loss of EpCAM expression at the
plasma membrane [22, 49]. Despite agreeing on the observed
phenotype, Lei et al. [48] and Guerra et al. [47] disagreed on
the molecular mechanisms. Lei et al. observed a loss of tight
junction formation owing to substantially reduced recruitment
of murine claudin 7 to tight junctions in the absence of
EpCAM [48]. These findings are supported by the direct in-
teraction of EpCAM with claudin 7 [50], which was demon-
strated to support tumor progression in colorectal cancer [51,
52]. Guerra et al. demonstrated a dysregulation of E-cadherin
and ß-catenin functions leading to partial disruption of
adherens junctions [47]. A cooperation of E-cadherin and
EpCAM in epithelial adhesion regulation is further supported
by work in zebrafish, where EpCAM knockout impaired the
integrity of the skin periderm through reduced cell surface
levels of E-cadherin and increased levels of tight junction
protein 1 (Tjp1) [53].
More discrepancies exist on EpCAM’s role in cell-cell ad-
hesion. Gaber et al. [54] could not confirm intercellular homo-
oligomers, despite formation of cis-dimers [54], leading to the
conclusion that EpCAM’s role in adhesion is not assumed as a
homophilic cell adhesion molecule. Furthermore, neither reg-
ulated intramembrane proteolysis of EpCAM nor EPCAM
knockout in cell lines had any measurable impact on cell-
matrix and cell-cell adhesion in cancer cells [33]. Hence,
EpCAM’s molecular function in adhesion has not been satis-
factorily resolved yet. EpCAM is undeniably involved in
maintenance of epithelial integrity in various animal models
and human conditions where it acts in concert with established
cell adhesion molecules. Therefore, EpCAM might support
cell adhesion primarily mediated by other molecules such as
claudins and cadherins, and/or might preferentially play a role
in adhesion of normal but not tumor cells.
4 EpCAM as a prognostic marker in cancer
EpCAM received considerable attention as a prognostic mark-
er based on its strong expression in various carcinomas and
their metastases as compared to normal epithelia of the same
localization [11–13]. EpCAM is highly and frequently
expressed in the vast majority of carcinomas that have been
analyzed [11, 12] and its expression in metastases frequently
correlates with levels in the corresponding primary tumors
(Fig. 4 and [13, 14, 21, 55]). As such, EpCAM bears potential
as a prognostic and therapeutic marker in carcinomas and
during cancer progression and metastasis formation.
However, EpCAM’s prognostic value varies depending on
the tumor entity. High expression in primary carcinomas is
associated with poor prognosis in breast [56, 57], colorectal
[58], prostate [59], gallbladder [60], ovarian [61], bladder
[62], pancreas [63, 64], and adenoid cystic carcinomas [65].
Oppositely, high expression of EpCAM is associated with
better prognosis in colonic [12], esophageal [66], renal [67,
68], gastric [69], endometrial [70], thyroid [71], and head and
neck carcinomas [72]. Multiple cellular functions of EpCAM
may deploy in dependency of tumor types and localization,
and might differently affect single cells within tumors. High
expression of EpCAM can promote sustained proliferation
and tumor/metastatic growth and might thereby be associated
with poor prognosis. EpCAM also represents a marker of
epithelial differentiation and might therefore associate with a
more differentiated, less migratory/invasive phenotypes, with
reduced resistance to irradiation and chemotherapy, and hence
with better survival. Therefore, EpCAM’s association with
differential clinical outcome is complex and might vary de-
pending on the origin of the tumor or even the stage of tumor
progression. This unsolved discrepancy in the prognostic val-
ue of EpCAM expression remains poorly understood and re-
quires further investigation.
Another essential aspect is that cancer-related lethality
is primarily caused by therapy-resistant cells and fre-
quently untreatable metastases. Numerous studies on
EpCAM’s prognostic value have initially concentrated
on primary tumors rather than disseminated cells [12,
57–65, 67–73]. However, primary tumor biopsies repre-
sent a specific region of the tumor at a given time point.
Based on growing evidence of intratumor heterogeneity
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and temporal variation in tumor antigen expression
[74–80], a singular measurement of primary tumors might
suffer from bias. Consequently, numbers of disseminated
tumor cells, which are considered primary sources of re-
lapse and metastases, have been implemented as addition-
al prognostic marker [81–83]. Here, tumor cells found in
the blood are termed circulating tumor cells (CTCs) and
tumor cells in distant organs, for example, in the bone
marrow, are termed disseminated tumor cells (DTCs).
Clinical assessment of CTCs in the blood is minimally
invasive and allows for longitudinal measurements [82,
84] and aims at the prediction of metastasis formation
[19]. Measurement of CTCs in the blood of metastatic
breast cancer (MCB) patients was performed using
EpCAM-specific antibodies for the enrichment of rare cir-
culating tumor cells, which were subsequently further
characterized by the expression of cytokeratins, presence
of a nucleus, and lack of white blood cell marker CD45.
CTC numbers in the blood showed prognostic value and
patients with five CTCs or more per 7.5 mL blood had
decreased overall and progression-free survival [18].
More recently, 3173 patients with non-metastatic (stages
I–III) breast cancer were analyzed and a CTC threshold of
≥ 1 cell per 7.5 mL of blood correlated with decreased
OS, disease-free survival, distant disease-free survival,
and cancer-specific survival [85]. The prognostic value
of EpCAM-positive CTCs has been confirmed for further
tumor entities, including lung cancer [86], advanced ovar-
ian cancer [87], gastric cancer [88], colorectal cancer [89],
and head and neck squamous cell carcinoma (HNSCC)
[90]. Hence, the enrichment of rare EpCAM-positive sys-
temic tumor cells in the blood in the frame of liquid bi-
opsies has the potential to evaluate disease outcome in-
cluding the patients’ burden of metastatic cells [20, 21,
85].
5 EpCAM as a target in clinical trials for cancer
therapy
EpCAM is highly and frequently expressed in the vast major-
ity of carcinomas, in tumor-initiating cells, and in disseminat-
ed tumor cells, which qualified EpCAM as a potential target
for cancer therapies [15, 91, 92]. Several publications demon-
strated that EpCAM-specific antibodies can eliminate cancer
cells by various mechanisms [93–102] and detect DTC in the
bone marrow of patients [103, 104]. Monoclonal antibody 17-
1A was clinically tested alone and in combination with γ-
interferon for the treatment of gastrointestinal and metasta-
sized colorectal carcinomas [105, 106]. Induction of complete
remissions by mAb 17-1A were reported in metastasized co-
lorectal cancer [107, 108]. Positive overall survival data with
mAb 17-1A in a pivotal study with metastasized colorectal
cancer patients [96, 99] resulted in approval of the antibody
in Germany under the trade name Panorex®. However, when
compared to standard care with 5-fluorouracil-based chemo-
therapy in a later trial [109], edrecolomab was found inferior,
leading to its market withdrawal. EpCAM-specific humanized
antibodies ING-1 and 3622W94, bearing higher binding af-
finity than edrecolomab, were tested in clinical trials but were
discontinued because of low tolerability. While edrecolomab
might have suffered from an insufficient binding affinity,
ING-1 and 3622W94 displayed too high affinity that no lon-
ger allowed to distinguish normal and malignant cells, leading
to pancreatitis [110, 111].
Micromet Inc. developed fully human IgG1 EpCAM-
specific antibody MT201 (adecatumumab) that had an inter-
mediate binding affinity for EpCAM in an attempt to improve
therapeutic efficacy [112]. Adecatumumab was investigated
as monotherapy in a phase II clinical trial in MBC patients.
Adecatumumab did not induce measurable tumor regression;
however, patients treated with high-dose antibody and
Fig. 4 EpCAM expression in
normal mucosa, primary head and
neck squamous cell carcinoma,
and lymph node metastasis.
Shown are
immunohistochemistry staining
of EpCAM in normal mucosa,
primary tumor, and lymph node




expressing high levels of EpCAM retrospectively showed re-
duced development of new metastases (3/18 versus 14/29 pa-
tients) [113]. In a dose-escalating phase I trial enrolling pros-
tate cancer patients, reduction of prostate-specific antigen
levels was observed [114]. While having a favorable safety
profile, the antibody program is no longer pursued because it
did not reach its clinical endpoints.
EpCAM was also targeted with T cell-engaging antibodies
designed to connect cytotoxic T cells with cancer cells for
redirected lysis. Antibody catumaxomab (Removab®) devel-
oped by Trion Pharma has an EpCAM- and a CD3-binding
arm and its Fc domain binds Fc gamma-receptor expressing
antigen-presenting cells [115]. Catumaxomab was approved
by the European Medicines Agency (EMA) to treat malignant
ascites [116], but was eventually terminated. MT110
(solitomab) is a tandem single-chain antibody construct com-
prised of an EpCAM- and CD3-specific binding domain de-
veloped by Micromet Inc. [117]. Pharmacokinetics, tolerabil-
ity, safety, and anti-tumor activity of MT110 were assessed in
a dose-escalating phase I clinical trial in metastatic colorectal,
gastric, and lung carcinomas (129) with disease stabilization
in 7/19 patients. Due to gastrointestinal toxicities, solitomab
could not be escalated to more efficacious dose levels, and the
program was abandoned.
Recently, EpCAM-specific antibody EpAb2-6 was de-
veloped, which binds to an epitope within the thyroglobulin
domain and demonstrated inhibitory potential [118].
EpAb2-6 induces apoptosis, inhibits tumor growth inmouse
models, and represses EpCAM cleavage to form the signal-
ing moiety EpICD in pancreatic and colon carcinoma cells
[118, 119]. Thus, EpAb2-6 is an anti-EpCAM antibody that
inhibits central EpCAM signaling functions, which might
represent a novel approach to treatment methods targeting
EpCAM in carcinomas. Furthermore, EpCAM-specific an-
tibodies were conjugated with bouganin (citatuzumab
bogatox) [120], Pseudomonas exotoxin A (oportuzumab
monatox) [121] and alpha-amanitin [122], with interleukin-
2 to activate T cells in the vicinity of EpCAM-positive tumor
cells (huKS-IL2) [123], and with encapsulated inhibitory
RNAs [124–126]. In 2015, a phase I clinical trial of patients
with EpCAM-positive metastatic cancers aimed at evaluat-
ing the maximum tolerated doses, pharmacokinetics, and
immunogenicity of the anti-EpCAM-based immunotoxin
MOC31PE that is coupled to Pseudomonas exotoxin A.
MOC31PE was intravenously combined with the immuno-
suppressant cyclosporin in n = 63 metastatic patients and
revealed a safe profile with a half-life in plasma of 3 h and a
reduction of [127]. Subsequently,MOC31PEwas applied to
address peritoneal metastasis in colorectal and ovarian can-
cers within the ImmunoPeCa phase I/II. Based on the prom-
ising cytotoxicity profile and a low systemic uptake,
MOC31PE is currently further evaluated in a clinical phase
II study [128, 129].
Further clinical trials including the usage of chimeric anti-
gen receptor T cells (CAR T cells) targeting EpCAM are on-
going in order to address their potential for the treatment of
recurrent and treatment-resistant solid tumors (https://
clinicaltrials.gov/ct2/show/NCT04151186). Currently, a total
of 64 clinical trials are listed by the US national library of
medicine that involve EpCAM as a biological using CAR T
cells , monoclonal antibodies, immunotoxins and
immunocytokines, and EpCAM-based capture methods to en-
rich CTCs (https://clinicaltrials.gov/ct2/results?cond=&term=
EpCAM&cntry=&state=&city=&dist=). While EpCAM
expression on most carcinoma is a highly attractive feature
for tumor-associated antigens, expression on healthy
epithelia—mostly of the gastrointestinal tract—will limit the
therapeutic window of EpCAM-targeted therapies and call for
potential side effects. A next generation of EpCAM-targeted
drugs that are selectively activated in the tumor microenviron-
ment may finally allow to leverage this target antigen [130].
Finally, EpCAM serves as a target for image-guided sur-
gery approaches that aim at improving resection margins.
Residual tumor cells following incomplete tumor removal at
the resection margin are a major source of local recurrence in
solid tumors [131]. The employed strategies include the sys-
temic application of EpCAM-specific antibodies labeled with
fluorescent dyes such as fluorescein isothiocyanate (FITC)
and near-infrared fluorescence dye (NIRF) IRDye800CW
[132, 133]. Fluorescence-labeled anti-EpCAM antibodies al-
low the detection of residual tumor nodules in the millimeter
size range using intraoperative imaging systems [133, 134].
6 Signaling of EpCAM
6.1 RIP-mediated EpCAM signaling
EpCAM regulates cell cycle progression and differentiation
via regulated intramembrane proteolysis (RIP). Initial cleav-
age of EpCAM is conducted bymembrane-resident ADAM (a
disintegrin and metalloproteinase) family proteases ADAM
10 and 17 (Fig. 5). Thereby, the ectodomain of EpCAM is
shed into the extracellular space as soluble EpEX [135]. The
resulting membrane-tethered C-terminal fragment (EpCAM-
CTF) is cleaved by the γ-secretase complex to form the ex-
tracellular, small, and soluble Aβ-like fragment and the intra-
cellular EpICD fragment [33, 34, 135]. EpICD translocates
into the nucleus and, in combination with transcription factors
and adaptor molecules such as FHL2, β-catenin, and Lef1,
binds to promoter regions of regulators of cell division (cyclin
D1 [136]), pluripotency genes [137–139], and genes involved
in the regulation of EMT-associated processes such as tight
junctions, adherence, and cell migration [140]. However, reg-
ulation of EpCAM cleavage and EpICD signaling through
activation of EGFR remains a matter of dispute [140–143].
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Interactions between ADAM 10 and EpCAM in the
tetraspanin web of human colon cancer cells were reported
before EpCAM RIP [144]. A role for ADAM 17 (tumor ne-
crosis factor-α-converting enzyme (TACE)) in EpCAM RIP
was demonstrated using biochemical approaches and TACE
inhibitors [135]. Chemical inhibition of ADAMs and TACE
knockdown prevented the first cleavage and reduced
EpCAM’s proliferative effects, which were restored through
ectopic expression of EpICD [135, 136]. Cleavage sites for
ADAM proteases (α-sites) were determined in human and
mouse EpCAM [33, 34]. Murine EpCAM has one major α-
site (serine230/lysin231), whereas human EpCAM has two (as-
partate243/proline244 and proline244/glycine245) [33, 34].
Additionally, the aspartyl protease BACE1 (beta-site amyloid
precursor protein-cleaving enzyme 1) cleaves human and mu-
rine EpCAM at position tyrosine250/tyrosine251 and tyro-
sine251/tyrosine252 (β-site), respectively (Fig. 3). BACE1 has
an optimal catalytic activity at pH 4 [145] and is therefore
active in acidified cytoplasmic vesicles [146]. Under acidic
conditions, cleavage of EpCAM is considerably more effi-
cient, and BACE1 overexpression resulted in enhanced
release of EpEX [34]. Based on superpositions of cleavage
sites on the crystal structure of human EpEX, α- and β-sites
are masked within EpEX dimers [3, 33, 147]. Superior cleav-
age by BACE1 could thus be facilitated owing to the reported
decomposition of EpEX dimers to monomers under acidic
conditions [3, 147]. However, quantitative contributions of
ADAM proteases and BACE1 to the cleavage of EpCAM
varied with the cell type [34].
Cleavage of ECAM-CTF is completed by the γ-secretase
complex comprising presenilin-2 as catalytic subunit [135]
(Fig. 5). Cleavages between residues Val273/Val274, Val274/
Val275, and Val275/Val276 in human EpCAM-CTF and be-
tween Ala271/Val272 and Val274/Val275 (γ-sites) in murine
EpCAM-CTF generate EpCAM-Aβ-like fragments.
Cleavages between residues Val284/Val285 and Leu286/Val287
in human EpCAM-CTF and between Val285/Val286, Leu287/
Val288, Val288/Iso289, and Ser290/Thr291 (ε-sites) in murine
EpCAM-CTF produce EpICD molecules [33, 34]. Initial ob-
servation of a preferential proteolysis in malignant versus
healthy colon tissue [135] was corroborated by independent
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Fig. 5 Schematic representation of the signaling mechanisms associated
with EpCAM. Signaling by EpCAM and degradation of EpCAM via
regulated intramembrane proteolysis (RIP) is depicted in the left part of
the scheme. Membrane-associated signaling, trafficking, and intracellular
RIP in endocytic vesicles are depicted on the right part. Effects of distinct
pathways and the associated molecules are color-coded and implemented
in the schematic representation of the cell nucleus
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adult liver cells, nor was it involved in regulating proliferation
of these cells [148]. Secondly, EpICD nuclear translocation in
various carcinomas correlated with more aggressive pheno-
types and poorer outcome [149–151]. Lastly, generation of
EpICD by γ-secretase is a particularly slow process with a
50% turnover of EpCAM-CTF between 0.75 and 5.5 h
[152], as shown for other γ-secretase substrates [153].
Furthermore, EpICD is a highly labile protein that is degraded
by the proteasome [34, 152], which might be controlled by
two ubiquitylation sites at lysine299 and lysine303 within
EpICD [154]. Based on all these findings, we believe RIP of
EpCAM is most probably involved in a lengthy signaling
process rather than in producing a signaling spike accompa-
nied by comprehensive degradation of EpCAM.
The existence of a membrane version of EpCAM that
is lacking the intracellular domain group has been report-
ed [63], which correlated with a more aggressive pheno-
type of colorectal and pancreatic cancers and with reduced
overall survival of the afflicted patients [58, 63].
Alternative EpCAM mRNA splicing was reported; how-
ever, none of these differentially spliced mRNAs would
encode the truncated version of EpCAM (https://www.
ncbi.nlm.nih.gov/ieb/research/acembly/av.cgi?db=
human&term=EPCAM&submit=Go). Alternatively,
rhomboid proteases and members of the signal peptide
peptidase-like proteases (SPPL3) can cleave their sub-
strates directly within the transmembrane domain. Thus,
rhomboids could produce an EpCAM variant devoid of
EpICD, but these proteases have only been demonstrated
to cleave type II membrane proteins, whereas EpCAM is a
type I membrane protein. Also, cleavage by SPPL3 and
rhomboids is expected to release the substrates’ extracel-
lular domains owing to the reduced hydrophobicity and
lack of retention in the plasma membrane. Schnell et al.
reported on γ-secretase-independent cleavage of EpCAM-
CTF variants by membrane-associated proteases [35],
which theoretically could cleave EpCAM without EpEX
shedding. They further described an additional EpCAM
cleavage at two sites within the cysteine-poor region that
can alternatively generate EpICD [35]. Alternatively, the
ectodomain of EpCAM may remain membrane-associated
through the interaction with a yet unknown membrane
component or post-translational modification such as ac-
ylation, which have not yet been described.
More recently, cleavage of EpCAM within the extra-
cellular domain by the membrane-tethered serine pepti-
dase matriptase was described [155]. Matriptase was
found to catalyze dibasic cleavage of EpCAM between
arginines 80 and 81, reducing the interaction of EpCAM
with claudin-7 inducing its destabilization. This event
has the potential to contribute to the disruption of the
epithelial integrity of mouse intestine in CTE [156,
157].
6.2 Signaling by intact EpCAM
Intact EpCAM also signals through associated intracellular
proteins. The regulatory p85 subunit of phosphatidylinositol
3-kinase (PI3K) shifts its binding affinity from N-cadherin to
EpCAM following overexpression of the latter [45]. The
EpCAM/p85 complex displayed kinase activity, suggesting
a signaling pathway of EpCAM involving activation of
PI3K [45]. More recently, the embryonic Ras GTPase
(ERas) was isolated as an interaction partner of EpCAM in
murine teratocarcinoma cells [158]. EpCAM and ERas are
expressed in pluripotent ESC and in single cells of the epiblast
and visceral endoderm of murine embryos and are co-
regulated at the early onset of gastrulation [158]. EpCAM/
ERas interaction was associated with enhanced activating
phosphorylation of AKT at serine473, and cellular knockout
of EpCAM resulted in diminished AKT phosphorylation
[158]. Furthermore, EpCAM levels regulate the activating
phosphorylation of NF-κB subunit Rel A, destabilization of
the inhibitor of κB (IκB), and ultimately control interleukin-8
(IL-8) expression [159]. IL-8 in turns was instrumental in the
regulation of EpCAM-dependent cell invasion and positively
correlated with EpCAM expression inmetastatic breast cancer
[159].
Thus far, we have a limited understanding of ligands that
activate EpCAM signaling. EpEX is the only known extracel-
lular ligand inducing the RIP of EpCAM [135]. Cell-cell con-
tact likewise induced EpCAMRIP [160]. Additional extracel-
lular cues originating from tumor cells and/or cells of the
tumor microenvironment remain elusive.
6.3 Spatiotemporal expression of EpCAM in normal
tissue and carcinomas
Decades after its discovery on cancer cells, EpCAM was
found to be highly expressed on murine and human ESCs
[161, 162], and on murine embryonic germ cells [163]. High
levels of EpCAM correlate with the pluripotent state of ESCs
[137, 161, 162] and with the re-acquisition of pluripotency
during reprogramming of somatic cells [138, 139, 164]. In
fac t , the uphold co-express ion of EpCAM with
reprogramming factors Nanog and Sox2 is mandatory for so-
matic cells to progress towards reprogrammed induced plurip-
otent stem cells (iPSCs) [165].
Single-cell RNA sequencing disclosed that EpCAM is
expressed in cells of the inner cell mass (ICM) at gestation
day E3.5 of mouse embryogenesis [158]. Epiblast, primitive
and visceral endoderm, and earliest cells of the forming prim-
itive streak express EpCAM, although to levels that are re-
duced compared to ICM cells. With the onset of gastrulation
at E6.5, EpCAM expression was strongly reduced or absent in
early mesodermal cells [158]. In Xenopus, EpCAM controls
cell movements during embryonic development in the three
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germ layers [166]. Overexpression of EpCAM in a gain-of-
function mutation in meso- and ectodermal cells enhanced
their invasive potential and thereby induced an intermixing
of the cell types based on the repression of the activity of novel
protein kinase C variants [166, 167].
At later stages of murine embryogenesis (> E8.5), EpCAM
expression was primarily detected in murine endodermal tis-
sue [46, 158]. Spatiotemporal regulation of EpCAM expres-
sion was reproduced in murine ESCs after spontaneous differ-
entiation in EBs and confirmed the lack of EpCAM in
vimentin-positive mesodermal cells and its retention in
Foxa2/Gata4-positive endodermal cells [158]. Balanced
EpCAM expression in differentiating ESC appears mandatory
as the co-existence of EpCAM-positive endodermal cells and
EpCAM-negative mesodermal cells was required for full ESC
differentiation [158]. Interference with this controlled expres-
sion yielded ESCs with reduced pluripotency and differentia-
tion capacity, and with impaired capability to generate
cardiomyocytes [158, 161]. Disturbance of ERas expression
hampered spontaneous ESC differentiation in similar fashion
[158], suggesting that EpCAM/ERas signaling is required in
murine ESC for full pluripotency. The requirement of
EpCAM-positive and EpCAM-negative cells for the develop-
ment of contracting cardiomyocytes confirmed previous re-
ports [168–170]. Through transcription factor Gata4,
EpCAM-positive visceral and definitive endoderm is formed
from pluripotent ESCs [168]. Both endoderm types support
the generation of cardiomyocytes from mesodermal cells
through the production of cardiac-inducing factors, and them-
selves differentiate towards liver progenitors [168, 169].
Accordingly, mature hepatocytes lack EpCAM, whereas hu-
man hepatic progenitors express EpCAM [171, 172] without
activating it through RIP [148]. EpCAM’s role in hepatocyte
differentiation was uncovered in zebrafish, where EpCAM is
enriched in endodermal cells and counteracts the repression of
WNT signaling to induce hepatocyte differentiation.
Molecularly, EpCAM blocks Kremen-1 and Dickkopf-2 in-
teractions through sequestration of Kremen-1, preventingWnt
receptor Lrp6 (lipoprotein receptor-related protein 6) with-
drawal from the plasma membrane. As a result, Wnt2bb sig-
naling is activated and promotes hepatocyte differentiation
from endodermal cells [173].
Hence, spatiotemporal expression and functions of
EpCAM during embryogenesis are tightly regulated and re-
quired for the proper development of endo- and mesodermal
cells in cell-autonomous and non-autonomous ways.
6.4 Regulation of EpCAM in cancer progression: the
EMT path and metastasis formation
In line with an absence of EpCAM in mesodermal cells, fre-
quent loss of EpCAM occurs in malignant cells undergoing
EMT [174–176]. First reports of a transient EpCAM
regulation in cancer progression came from xenotransplanta-
tion models. Primary tumors and larger metastases (≥ 30 cells)
expressed high levels of EpCAM, whereas smaller metastases
(< 15 cells) lacked EpCAM [55]. Loss of EpCAM coincided
with increased expression of mesenchymal marker vimentin
in primary human tumors [72, 174, 176] and in disseminated
tumor cells [21, 177, 178]. Because EMT is neither an all-or-
nothing process nor does it apply to the totality of malignant
cells in a tumor, EMT promotes inter- and intratumor hetero-
geneity [74, 80, 174, 179, 180], fostering tumor progression,
metastasis formation, and therapy resistance within subsets of
cells [76, 174, 180, 181]. An involvement of EMT in the
metastatic cascade implies the transient and reversible acqui-
sition of migratory and invasive traits by subsets of tumor cells
through a partial mesenchymal transition that can be regulated
at the epigenetic level [179, 182]. Alternatively, pre-existing
subsets of tumor cells in an EMT state are present at earliest
stages of tumor formation and represent metastatic progenitors
that can co-evolve within primary tumors [183] or at distant
sites following early detachment from primary tumors [184].
It must also be noted that the actual contribution of EMT to the
metastatic cascade is a matter of strong debate [179] with
reports on the lack of requirement for a mesenchymal shift
for the generation of distant metastases [185, 186].
Single-cell RNA-seq of oropharyngeal carcinomas uncov-
ered a huge degree of inter- and intratumor heterogeneity at
the transcriptome level [187]. A signature of partial EMT as-
sociated with metastasis formation and poor prognosis and
was inversely correlated with a signature of epithelial differ-
entiation in which EpCAM was a major determinant [187].
Functionally, tumor cells in an EMT state are more refractory
to therapy and possess increased migratory and invasive traits,
supporting local and distant dissemination [179, 181, 187,
188]. Eventually, metastatic outgrowth requires that dissemi-
nated tumor cells re-adopt a proliferative, epithelial phenotype
that is associated with the reversion of EMT (i.e., MET). In
summary, EMT emerged as a transient state with gradual
changes, which strongly contributes to tumor progression
and which can be monitored using a panel of dominant
markers including EpCAM.
Changes along the EMT path involving loss of EpCAM are
likewise observed in CTCs [177, 178] and DTCs [189]. This
may have repercussions at two levels: (i) loss of EpCAM in
CTCs undergoing EMT will hamper their detection using the
EpCAM-based CellSearch enrichment system and (ii) it raises
the question as to whether EpCAM-negative CTCs and DTCs
have metastatic potential. Clinical studies on CTCs using
CellSearch underscored the prognostic value of EpCAM-
positive CTCs in various cancers [20, 21, 82, 84–90]. A study
in castration-resistant prostate cancer and MBC patients re-
vealed that the frequency of EpCAM-low CTCs was not cor-
related with the patients’ overall survival, while of EpCAM-
high CTC frequency was associated with poor overall survival
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[190]. CTCs and DTCs with differing EMT status—as mea-
sured by EpCAM expression—were likewise detected in a
mouse model of MBC [21]. EpCAM-positive CTCs with an
epithelial phenotype and a restricted mesenchymal shift
showed the highest metastatic potential and were associated
with distant metastases and poorer survival in MBC patients
[21]. In contrast, the increase of EMT-type CTCs in MBC
patients correlated with disease progression following therapy
[178], and mouse-derived mesenchymal-type CTCs were less
susceptible to chemotherapeutic drugs in vitro [21]. In conclu-
sion, a variety of EMT types of CTCs and DTCs appear to
coexist in individual animals and in patients, which can be
classified using EpCAM as a marker. From the most recent
reports, it seems that rather epithelial-type CTCs are the
source of metastases, whereas more mesenchymal-type
CTCs represent treatment-resistant cells.
In addition to being a valuable marker for the EMT status
of tumor cells, EpCAM is also functionally involved in the
regulation of EMT. A double-negative feedback loop, in
which activated extracellular regulated kinase 2 (Erk2) direct-
ly and indirectly repressed the transcription of EPCAM
through binding to its promoter region and through the induc-
tion of EMT transcription factors that repress EPCAM tran-
scription, was reported [30]. EpCAM on the other hand re-
pressed ERK activation and thereby dampened EMT induc-
tion [30]. In nasopharyngeal carcinomas, high expression of
EpCAM correlated with metastasis formation in vitro and
in vivo but had no effect on cell proliferation. Strong expres-
sion of EpCAM promoted EMT and a cancer stem cell phe-
notype in association with increased migration and invasion,
via the activation of AKT,mTOR, p70S6K, and 4EBP1 [191].
In colon cancer cell lines, the expression of EpCAM enhanced
the transcription of reprogramming factor genes c-Myc,
Oct3/4, Sox2, and Nanog, and the EMT regulators Snail and
Slug through EpICD signaling [192].
Activation of EpCAM RIP through EGFR signaling was
described in endometrial cells, which eventually results in the
release of EpICD and the activation of EMT-relevant genes in
cooperation with transcription factor LEF-1 [140]. For un-
known reasons, the reported cleavage of EpCAM following
EGF treatment could not be reproduced in a variety of carci-
noma cell lines [143]. However, a functional connection of
EpCAM and EGFR emerged very recently. We demonstrated
that EGFR has a dual capacity to either induce proliferation or
EMT in HNSCC cells, a phenomenon that was dependent
upon the strength of activation of the downstream effector
kinase Erk1/2 [143]. EpEX was revealed as a novel EGFR
ligand in HNSCC [143] and in colon cancer cells [119].
EpEX induces classical EGFR-mediated pathways (i.e.,
AKT and Erk) but induces Erk1/2 activation to a lesser extent
than EGF in HNSCC cell lines, resulting in a mild cell prolif-
eration but no EMT. In contrast, treatment of HNSCC cell
lines with EMT-inducing concentrations of EGF and
equimolar amounts of EpEX blocked EMT through decreased
Erk1/2 activation [143]. Patients suffering from EGFRhigh/
EpCAMlowHNSCCwere characterized by very poor survival,
whereas EGFRlow/EpCAMhigh patients had an excellent clin-
ical outcome [143]. Furthermore, EpEXwas shown to activate
EpCAMRIP via EGFR signaling, resulting EpICD generation
[119]. EpICD was required for β-catenin accumulation in the
nucleus and for activation of hypoxia-inducible factor 1 alpha
(HIF1α). Accordingly, nuclear localization of EpICD in colon
carcinoma patients was associated with metastasis formation
and worsened clinical outcome [119]. Interestingly, anti-
EpCAMmonoclonal EpAb2-6 inhibited nuclear translocation
of EpICD and induced apoptosis. Thus, EpAb2-6 might rep-
resent a novel and promising treatment to reduce metastasis
formation in patients at risk [119].
Lastly, EpEX binding to EGFR promoted the multipotency
of mesenchymal stem cells through enhancement of
pluripotency factors. Mechanistically, EpEX induced an
EGFR-dependent STAT3 activation and the blockade of
Let7 microRNA through upregulation of LIN28 [193]. As a
result, EpEX induces proliferation of bone marrow-derived
mesenchymal stem cells. Hence, EpCAM regulates the fate
of various stem cells through multiple mechanisms including
membrane-associated signaling and as a ligand of EGFR.
Furthermore, EpCAM is regulated during EMT and is itself
a regulator of this trans-differentiation program in carcinoma
and stem cells. Several modes of action have been reported
that involve RIP products EpEX and EpICD, and full-length
EpCAM. Interestingly, EMT-promoting and EMT-repressing
functions of EpCAM have been described, a controversy that
deserves further investigation.
7 Perspective
In the future, we expect further insight in the role of EpCAM
in the regulation of cell fate in health and disease, which
would eventually revive its usage as therapeutic target. The
discovery of RIP of EpCAM and the generation of the
signaling-active fragments EpEX and EpICD paved the way
for a novel class of EpCAM inhibitors that target signaling in
cancer and the metastatic cascade. Antagonizing antibodies
such as EpAb2-6 and small molecule inhibitors that compete
with EpCAM RIP or with EpICD functions could develop
into promising candidate drugs for the treatment of EpCAM-
positive carcinomas and the formation of lethal metastases.
EpCAM will retain a central role as of anchor molecule in
the enrichment of CTCs that harbor metastatic potential in
advanced cancer patients. Here, EpCAM has dual potential
as a quantifier of systemic tumor cells in the frame of liquid
biopsies and as a potential target for adjuvant therapy of re-
sidual tumor cells with specific biologicals.
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Clinical studies on the predictive potential of EpCAM for
carcinoma entities associated with a high degree of treatment
resistance are required for the use of EpCAM as biomarker in
clinical decision-making. For example, prospective studies on
the expression of EGFR and EpCAM might shed light on the
power of EpCAM expression to predict treatment response in
carcinoma entities that implement a therapy with the anti-
EGFR monoclonal antibody cetuximab or small molecule in-
hibitors of EGFR.
In the future, the role of EpCAM in pluripotent stem cells
might gain momentum. Especially, the implication of
EpCAM and EpICD in the generation of iPS is of relevance.
Additionally, the use of EpEX in combination with the
reprogramming factors Klf4 or Oct3/4 was instrumental in
the generation of iPS and might therefore experience (pre-)-
clinical application.
Lastly, it can be anticipated that basic research on the ex-
pression dynamics and the molecular functions of EpCAM in
cancer and healthy cells will further support the
abovementioned clinical applications of this highly versatile
molecule.
8 Conclusion
Over the past four decades, EpCAM has evolved from a
humoral antigen expressed on the majority of carcinoma
cells to a complex signaling molecule involved in central
aspects of cell fate such as proliferation, pluripotency, dif-
ferentiation, and organ integrity. Signaling by intact
EpCAM and the proteolytic fragments EpEX and EpICD
as well as signaling-independent functions of EpCAM
serve these various purposes and represent novel handles
to tackle metastatic malignancies. Furthermore, EpCAM
remains an attractive target for antibody-based cancer ther-
apies and as a biomarker for patient stratification.
Importantly, EpCAM is the central target molecule for
the enrichment and characterization of systemic tumor
cells with prognostic and metastatic potential. Eventually,
EpCAM became a multifaceted protein with a long-
standing history in molecular oncology and in stem cell
biology.
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